Calliditas Therapeutics AB (publ)
CALT
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 104.56% | 55.18% | 6.03% | 10.47% | 292.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 104.56% | 55.18% | 6.03% | 10.47% | 292.84% |
| Cost of Revenue | 270.15% | 55.96% | 185.10% | 236.64% | 456.72% |
| Gross Profit | 95.34% | 55.15% | 2.67% | 6.65% | 286.51% |
| SG&A Expenses | 53.85% | 43.41% | 8.21% | 35.05% | 45.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 90.27% | -86.74% | -18.17% | -91.61% | -1,655.10% |
| Total Operating Expenses | 68.93% | 35.10% | 10.55% | 49.48% | 18.10% |
| Operating Income | 58.75% | -13.75% | -38.39% | -329.54% | 66.32% |
| Income Before Tax | 40.57% | -19.49% | -242.67% | -902.60% | 65.64% |
| Income Tax Expenses | -77.71% | 94.29% | -69.87% | 160.89% | 5,759.13% |
| Earnings from Continuing Operations | 49.16% | -31.92% | -402.62% | -1,701.91% | 55.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.16% | -31.92% | -402.62% | -1,701.91% | 55.38% |
| EBIT | 58.75% | -13.75% | -38.39% | -329.54% | 66.32% |
| EBITDA | 59.85% | -13.49% | -36.54% | -330.34% | 66.52% |
| EPS Basic | 49.20% | -31.90% | -395.38% | -1,691.98% | 55.76% |
| Normalized Basic EPS | 40.54% | -19.49% | -250.91% | -893.26% | 65.69% |
| EPS Diluted | 49.20% | -31.90% | -395.38% | -1,691.98% | 55.76% |
| Normalized Diluted EPS | 40.54% | -19.49% | -250.91% | -893.26% | 65.69% |
| Average Basic Shares Outstanding | 0.03% | 0.00% | 0.78% | 0.80% | 0.91% |
| Average Diluted Shares Outstanding | 0.03% | 0.00% | 0.78% | 0.80% | 0.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
